Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has earned an average recommendation of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $48.50.

A number of research analysts have recently issued reports on the company. Needham & Company LLC cut their price target on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Truist Financial initiated coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set a “buy” rating and a $49.00 price target for the company. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Leerink Partners initiated coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price for the company.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd boosted its stake in Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 427 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 418 shares in the last quarter. Hantz Financial Services Inc. increased its stake in Collegium Pharmaceutical by 51.8% during the 4th quarter. Hantz Financial Services Inc. now owns 2,602 shares of the specialty pharmaceutical company’s stock valued at $120,000 after purchasing an additional 888 shares in the last quarter. Assetmark Inc. raised its holdings in shares of Collegium Pharmaceutical by 9.3% in the first quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 335 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Collegium Pharmaceutical by 20.6% in the first quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company’s stock worth $167,000 after buying an additional 861 shares during the last quarter.

Collegium Pharmaceutical Stock Down 0.3%

NASDAQ COLL traded down $0.07 during trading on Friday, reaching $22.31. 100,653 shares of the company’s stock traded hands, compared to its average volume of 547,496. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The firm has a market cap of $726.41 million, a price-to-earnings ratio of 17.99 and a beta of 0.72. The company’s 50 day simple moving average is $29.41 and its two-hundred day simple moving average is $32.82. Collegium Pharmaceutical has a 12-month low of $21.65 and a 12-month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. The firm had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.68 EPS. As a group, sell-side analysts forecast that Collegium Pharmaceutical will post 6.19 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs.

Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain.